Newsroom

MUMBAI, India--(BUSINESS WIRE)--KKR to Acquire Leading Multi-Specialty Healthcare Provider Medicover India...

LONDON--(BUSINESS WIRE)--Thumba today announced a strategic partnership with Testhouse, a global leader in quality engineering and digital assurance....

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- NTTドコモビジネス株式会社(旧 NTTコミュニケーションズ株式会社、以下 NTTドコモビジネス)は、総務省から受託した調査研究事業※1の一環として、チリ共和国のチリ国営銅公社(Corporación Nacional del Cobre de Chile) (以下 CODELCO)が運営する銅鉱山において、IOWN® APN※2を活用した遠隔オペレーション高度化に向けた調査・実証(以下 本取り組み)を開始します。 本取り組みでは、CODELCOが抱える銅鉱山運営上の課題の解決に向けて、銅鉱山と遠隔オペレーションセンター間、約1,500kmをIOWN® APNで接続し、大容量・低遅延通信環境を活用した重機の遠隔操作や高精細映像を用いた監視業務の高度化、ならびに遠隔運用モデルの実現可能性について検証します。 1．背景 チリは世界有数の銅生産国であり、CODELCOは同国を代表する銅生産企業ですが、近年、銅鉱山運営の安全性向上およびオペレーション効率化が重要な経営課題となっています。特に地下鉱山では、崩落事故などのリスク...

TOKYO--(BUSINESS WIRE)--NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 To address operational challenges faced by CODELCO’s copper mines, the initiative...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading quantum platform company, today announced that Capella, an IonQ company, has been awarded a contract under the National Reconnaissance Office’s (NRO) Radar Commercial Augmentation (RCA) program. Under the contract, the company will provide commercial synthetic aperture radar (SAR) imagery and data services in support of U.S. national security missions. The award strengthens the company’s national security portfolio by ex...

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ) announced today that it has been awarded a $28 million contract extension through the Defense Advanced Research Projects Agency (DARPA) It’s About Time program. Under the program, IonQ will advance its scalable clock production capabilities for its Evergreen-05 optical atomic clocks and deliver 125 units to U.S. government customers. The clocks are designed for mission-critical applications including radar, secure communications, and precisi...

TORONTO--(BUSINESS WIRE)--Celestica Inc. (NYSE: CLS) (TSX: CLS) (“Celestica” or the “Company”), a global leader in data center infrastructure and advanced technology solutions, today announced the pricing of its previously announced equity offering of 9,677,419 common shares at a price to the public of $310 per share (the “Offering”). The gross proceeds from the Offering, before underwriting discounts and Offering expenses, are expected to be $3,000,000,000. Celestica has granted the underwrite...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Alarum Technologies Ltd. (NASDAQ: ALAR) securities between March 20, 2025 and July 2, 2026 (the "Class Period"). Alarum contends to be global provider of web data collection solutions, empowering organizations to gain a competitive edge by streamlining the collection, extraction, and analysis of large-scale structured...

SAN FRANCISCO--(BUSINESS WIRE)--First paragraph, second sentence should read: The investment was co-led by Draper Associates and KAS Venture Partners, with participation from General Catalyst, Hanwha Asset Management Venture Fund, Outlander, Alumni Ventures, Bravo Victor Venture Capital (BVVC), Detroit Venture Partners, Decisive Point, among other investors. The updated release reads: AURELIUS SYSTEMS SECURES $40M SERIES A TO MEET GROWING DEMAND FOR COUNTER-DRONE SYSTEMS Aurelius Systems today...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, inc...